[Carrier-state of group B streptococcus in pregnant women--performance standards]

Karol Szwabowicz1, Anatol Panasiuk

  • 1Klinika Chor6b Zakaźnych i Hepatologii, Uniwersytet Medyczny w Białymstoku.

Insights

Group B Streptococcus (GBS) causes neonatal infections, with screening via ano-vaginal swabs during pregnancy identifying at-risk infants. Prompt antibiotic prophylaxis for GBS-positive mothers reduces neonatal sepsis risk.

Area of Science:

  • Microbiology
  • Neonatal Medicine
  • Infectious Diseases

Context:

  • Group B Streptococcus (GBS) is a leading cause of invasive neonatal infections.
  • Maternal colonization with GBS poses a significant risk for neonates, increasing sepsis risk 25-fold.
  • Screening via ano-vaginal swabs between 35-37 weeks gestation is crucial for risk assessment.

Purpose:

  • To review current epidemiology, diagnosis, prophylaxis, and treatment standards for GBS infections.
  • To outline the importance of intrapartum chemoprophylaxis based on GBS carrier status and risk factors.
  • To detail diagnostic and empirical treatment approaches for suspected neonatal GBS infections.

Summary:

  • GBS colonization in pregnant women necessitates screening to identify at-risk neonates.
  • Intravenous antibiotic administration at least 4 hours before delivery is recommended for GBS-positive mothers.
  • Neonates born to GBS-positive mothers require observation, with prompt diagnostic evaluation and empirical treatment if symptoms arise.

Impact:

  • Informed clinical decision-making regarding GBS screening and management.
  • Reduced incidence of early-onset neonatal sepsis due to GBS.
  • Improved outcomes for neonates exposed to or infected with Group B Streptococcus.